Firstline treatment for chronic phase chronic myeloid leukemia patients should be based on a holistic approach

被引：5

作者：

Breccia, Massimo ^{[1
]}

Alimena, Giuliana ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00161 Rome, Italy

来源：

EXPERT REVIEW OF HEMATOLOGY | 2015年 / 8卷 / 01期

关键词：

chronic myeloid leukemia; holistic approach; therapy; CHARLSON COMORBIDITY INDEX; FOLLOW-UP; IMATINIB; DISEASE; MANAGEMENT; DASATINIB; TRIAL;

D O I：

10.1586/17474086.2015.987230

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

New selective and more potent drugs for the cure of chronic phase chronic myeloid leukemia patients are now available: physicians in some countries must decide the best option, selecting one of the drugs available. What the main prognostic factors are in order to make this selection remains a matter of discussion. Introducing a holistic approach' for the first time in chronic myeloid leukemia, as practiced in other diseases, and looking at the patient in a complete picture, considering several variables, such as comorbidities, age, concomitant drugs, lifestyle and patient expectations, may be of help to understand, patient by patient, the best therapeutic strategy.

引用

页码：5 / 7

页数：3

共 14 条

[1] European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 [J].

Baccarani, Michele ;

Deininger, Michael W. ;

Rosti, Gianantonio ;

Hochhaus, Andreas ;

Soverini, Simona ;

Apperley, Jane F. ;

Cervantes, Francisco ;

Clark, Richard E. ;

Cortes, Jorge E. ;

Guilhot, Francois ;

Hjorth-Hansen, Henrik ;

Hughes, Timothy P. ;

Kantarjian, Hagop M. ;

Kim, Dong-Wook ;

Larson, Richard A. ;

Lipton, Jeffrey H. ;

Mahon, Francois-Xavier ;

Martinelli, Giovanni ;

Mayer, Jiri ;

Mueller, Martin C. ;

Niederwieser, Dietger ;

Pane, Fabrizio ;

Radich, Jerald P. ;

Rousselot, Philippe ;

Saglio, Giuseppe ;

Saussele, Susanne ;

Schiffer, Charles ;

Silver, Richard ;

Simonsson, Bengt ;

Steegmann, Juan-Luis ;

Goldman, John M. ;

Hehlmann, Ruediger .

BLOOD, 2013, 122 (06) :872-884

[2] Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer [J].

Birim, Ö ;

Kappetein, AP ;

Bogers, AJJC .

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2005, 28 (05) :759-762

[3] Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib [J].

Breccia, Massimo ;

Latagliata, Roberto ;

Stagno, Fabio ;

Luciano, Luigiana ;

Gozzini, Antonella ;

Castagnetti, Fausto ;

Fava, Carmen ;

Cavazzini, Francesco ;

Annunziata, Mario ;

Rossi, Antonella Russo ;

Pregno, Patrizia ;

Abruzzese, Elisabetta ;

Vigneri, Paolo ;

Rege-Cambrin, Giovanna ;

Sica, Simona ;

Pane, Fabrizio ;

Santini, Valeria ;

Specchia, Giorgina ;

Rosti, Gianantonio ;

Alimena, Giuliana .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (10) :1457-1461

[4] Estimation of ten-year risk of fatal cardiovascular disease in Europe:: the SCORE project [J].

Conroy, RM ;

Pyörälä, K ;

Fitzgerald, AP ;

Sans, S ;

Menotti, A ;

De Backer, G ;

De Bacquer, D ;

Ducimetière, P ;

Jousilahti, P ;

Keil, U ;

Njolstad, I ;

Oganov, RG ;

Thomsen, T ;

Tunstall-Pedoe, H ;

Tverdal, A ;

Wedel, H ;

Whincup, P ;

Wilhelmsen, L ;

Graham, IM .

EUROPEAN HEART JOURNAL, 2003, 24 (11) :987-1003

[5] PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE [J].

FEINSTEIN, AR .

JOURNAL OF CHRONIC DISEASES, 1970, 23 (07) :455-+

[6] Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party [J].

Gugliotta, Gabriele ;

Castagnetti, Fausto ;

Palandri, Francesca ;

Breccia, Massimo ;

Intermesoli, Tamara ;

Capucci, Adele ;

Martino, Bruno ;

Pregno, Patrizia ;

Rupoli, Serena ;

Ferrero, Dario ;

Gherlinzoni, Filippo ;

Montefusco, Enrico ;

Bocchia, Monica ;

Tiribelli, Mario ;

Pierri, Ivana ;

Grifoni, Federica ;

Marzocchi, Giulia ;

Amabile, Marilina ;

Testoni, Nicoletta ;

Martinelli, Giovanni ;

Alimena, Giuliana ;

Pane, Fabrizio ;

Saglio, Giuseppe ;

Baccarani, Michele ;

Rosti, Gianantonio .

BLOOD, 2011, 117 (21) :5591-5599

[7] Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management [J].

Jabbour, Elias ;

Kantarjian, Hagop .

AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (05) :547-556

[8] Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) [J].

Kantarjian, Hagop M. ;

Shah, Neil P. ;

Cortes, Jorge E. ;

Baccarani, Michele ;

Agarwal, Mohan B. ;

Soledad Undurraga, Maria ;

Wang, Jianxiang ;

Kassack Ipina, Juan Julio ;

Kim, Dong-Wook ;

Ogura, Michinori ;

Pavlovsky, Carolina ;

Junghanss, Christian ;

Milone, Jorge H. ;

Nicolini, Franck E. ;

Robak, Tadeusz ;

Van Droogenbroeck, Jan ;

Vellenga, Edo ;

Bradley-Garelik, M. Brigid ;

Zhu, Chao ;

Hochhaus, Andreas .

BLOOD, 2012, 119 (05) :1123-1129

[9] Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up [J].

Larson, R. A. ;

Hochhaus, A. ;

Hughes, T. P. ;

Clark, R. E. ;

Etienne, G. ;

Kim, D-W ;

Flinn, I. W. ;

Kurokawa, M. ;

Moiraghi, B. ;

Yu, R. ;

Blakesley, R. E. ;

Gallagher, N. J. ;

Saglio, G. ;

Kantarjian, H. M. .

LEUKEMIA, 2012, 26 (10) :2197-2203

[10]

Latagliata R, 2013, BLOOD, V122, P4002

← 1 2 →